To access the full text documents, please follow this link: http://hdl.handle.net/2445/127424
dc.contributor.author | Díaz Beyà, Marina |
---|---|
dc.contributor.author | Brunet, Salut |
dc.contributor.author | Nomdedéu Guinot, Josep Francesc |
dc.contributor.author | Cordeiro Santanach, Anna |
dc.contributor.author | Tormo, Mar |
dc.contributor.author | Escoda, Lourdes |
dc.contributor.author | Ribera, Josep Maria |
dc.contributor.author | Heras, Inmaculada |
dc.contributor.author | Gallardo Giralt, David |
dc.contributor.author | Bargay, Joan |
dc.contributor.author | Queipo de Llano, María Paz |
dc.contributor.author | Salamero, Olga |
dc.contributor.author | Martí, Josep María |
dc.contributor.author | Sampol, Antonia |
dc.contributor.author | Pedro, Carme |
dc.contributor.author | Hoyos Colell, Montserrat |
dc.contributor.author | Pratcorona, Marta |
dc.contributor.author | Castellano, Joan Josep |
dc.contributor.author | Nomdedeu i Fàbrega, Meritxell |
dc.contributor.author | Risueño, Ruth M. |
dc.contributor.author | Sierra Gil, Jorge |
dc.contributor.author | Monzó Planella, Mariano |
dc.contributor.author | Navarro Ponz, Alfons |
dc.contributor.author | Esteve Reyner, Jordi |
dc.contributor.author | Arnan, Montserrat |
dc.date | 2019-01-18T11:41:29Z |
dc.date | 2019-01-18T11:41:29Z |
dc.date | 2015-10-02 |
dc.date | 2019-01-18T11:41:31Z |
dc.identifier | 2044-5385 |
dc.identifier | 654364 |
dc.identifier | 26430723 |
dc.identifier.uri | http://hdl.handle.net/2445/127424 |
dc.description | Acute myeloid leukemia (AML) is a heterogeneous disease whose prognosis is mainly related to the biological risk conferred by cytogenetics and molecular profiling. In elderly patients (>= 60 years) with normal karyotype AML miR-3151 have been identified as a prognostic factor. However, miR-3151 prognostic value has not been examined in younger AML patients. In the present work, we have studied miR-3151 alone and in combination with BAALC, its host gene, in a cohort of 181 younger intermediate-risk AML (IR-AML) patients. Patients with higher expression of miR-3151 had shorter overall survival (P = 0.0025), shorter leukemia-free survival (P = 0.026) and higher cumulative incidence of relapse (P = 0.082). Moreover, in the multivariate analysis miR-3151 emerged as independent prognostic marker in both the overall series and within the unfavorable molecular prognostic category. Interestingly, the combined determination of both miR-3151 and BAALC improved this prognostic stratification, with patients with low levels of both parameters showing a better outcome compared with those patients harboring increased levels of one or both markers (P = 0.003). In addition, we studied the microRNA expression profile associated with miR-3151 identifying a six-microRNA signature. In conclusion, the analysis of miR-3151 and BAALC expression may well contribute to an improved prognostic stratification of younger patients with IR-AML. |
dc.format | application/pdf |
dc.language | eng |
dc.publisher | Springer Nature |
dc.relation | Reproducció del document publicat a: https://doi.org/10.1038/bcj.2015.76 |
dc.relation | Blood Cancer Journal, 2015, vol. 5, p. e352 |
dc.relation | https://doi.org/10.1038/bcj.2015.76 |
dc.rights | cc-by (c) Diaz Beya, Marina et al., 2015 |
dc.rights | http://creativecommons.org/licenses/by/3.0/es |
dc.rights | info:eu-repo/semantics/openAccess |
dc.subject | Leucèmia mieloide |
dc.subject | Pronòstic mèdic |
dc.subject | Malalts de càncer |
dc.subject | Micro RNAs |
dc.subject | Myeloid leukemia |
dc.subject | Prognosis |
dc.subject | Cancer patients |
dc.subject | MicroRNAs |
dc.title | The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia |
dc.type | info:eu-repo/semantics/article |
dc.type | info:eu-repo/semantics/publishedVersion |